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Biotechnologies represent a typical case of generic technology with high scientific content that 
spreads throughout a large part of the production system.1 Their development is thus a major 
stake in international competitiveness. They offer a privileged domain for the application of 
Kline and Rosenberg's model of innovation loops, which highlights the two-way connections 
between the S&T arena and industry. In the life sciences, the technological and R&D aspects 
are located both upstream and downstream in relation to research: upstream for the use of 
organisms or living components to analytical ends, or for the perfection of biological research 
instruments  (automation,  computer  science,  detectors,  biological  and  medical  engineering, 
etc.),  and  downstream  through  biotechnological  applications  resulting  from  advances  in 
scientific knowledge or the industrial development of innovative equipment and procedures 
contributing to scientific production.  
 
The mastery of the development of biotechnologies entails transformations in the organisation 
of  scientific  production  which  are  related  to  several  different  dimensions  that  are  now 
combining to determine their evolution :  
 
  The need for a multidisciplinary combination of knowledge and skills; 
  The increasing returns on the recourse to biotechnological knowledge, where the most 
recent discoveries do not replace the old ones but combine with and systematise them; 
                                                            
1. The term biotechnologies is used here in the sense of the utilisation of molecules or living organisms for 
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  Changes in the production methods of biological science (automation, computerisation), 
which  lead  to  an  increasing  methodological  codification  (catalogues)  of  biological 
elements, thus permitting responses to specific demands; 
  The  considerable  proximity  between    fundamental  knowledge  and  a  wide  range  of 
innovative  industrial  applications  (agrochemical,  pharmaceutical,  or  environmental), 
which are gradually coming to light. In fact, biotechnologies are rooted in the academic 
milieu  while  interacting  with  the  industrial  milieu.  They  thus  constitute  a  crossroads 
between one world whose rationale is supposed to be the preservation of diversity and 
another  whose  rationale  is  standardisation.  In  economic  terms,  the  systematisation  of 
biological  knowledge    can  permit  very  specialised  supply  zones  to  expand, generally  
through academic spin-offs, while also allowing  industrial groups seeking economies of 
scale to homogenise their  production through biology's "new direction". 
 
This  tension  between  the  tendency  towards  standardisation  and  a  preservation  of 
diversification (the research-biotechnologies-industry linkage) is controlled by the forms of 
interaction  between  public  action  schemes  rooted  in  institutional  frameworks  and  new 
configurations of players composed of laboratories, universities, facilities and firms, which 
may be organised in networks and/or physically localised. 
 
The  elaboration  of  scientific  knowledge  and  practices  about  living  organisms  and  their 
transfer  into  marketable  technology  are    situated  in  a  specific  institutional  context,  the 
effectiveness of which depends on the forms of linkage between the scientific research system 
and the other components of the innovation system (Amable, Barré, Boyer 1997). 
The aim of our research on innovation in genomics and biomedical related biotechnologies 
was to study this phenomenon in the French societal context : first of all for the 1985-1996 
decade,  which  marked  the  pioneering  phase  of  contemporary  molecular  biology,  its 
biotechnological  tools  and  its  biomedical  applications,  and  then  for  a  second  phase  of 
institutional reforms, after 1996. We shall demonstrate that this decade, in spite of its apparent 
ineffectiveness in the science-innovation tandem (part 1), nonetheless offered the prerequisites 
for a new technological policy of integration between public and private research and industry 
(part 2), as exemplified by the creation of an international center for research and development 
in  genomics  and  biotechnologies  in  Evry.  Within  this  framework,  the  first  section  (1.1.) 
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practice in France, by government action. This effort, which was short term and sporadic, 
nonetheless drew its effectiveness from the fact that it was reinforced by the preponderant 
impetus of a private player from the non-profit sector. The second section (1.2.) argues that, as 
in  Germany  (Casper  1999),  the  weakness  of  the  biotechnologies  sector  in  France  is  a 
consequence  of  the  institutional  frameworks  created  by  the  public  authorities  and  the 
strategies of industrial groups. The third section (2.1.) traces the emergence in France of an 
"ideal model" of research-innovation linkage, tied to the interdependency and diffusion of 
scientific  and  technical  advances  and  to  the  organisational  learnings  emerging  from 
globalisation. The fourth section (2.2.) analyses the successive institutional reforms, whose 
implementation is shaped by the societal appropriation of the "model" according to existing 
French institutional features. 
 
1  1985-1996 : THE CREATION OF A SCIENTIFIC AND TECHNICAL 
SPACE FOR GENOMICS, BUT NOT A SPACE FOR INNOVATION 
 
In 1985, the launching of the Human Gene (HG) sequencing project in the United States 
(followed in 1988 on the international level by the organisation HUGO) gave rise to polemics 
in France and brought out cleavages within the scientific community between  fundamental 
biology,  which  studies  the  functioning of genomes and their development,  most often on 
model  organisms,  and  applied  genetics,  with  its  "utilitarian  mission"  of  studying  genome 
anomalies  and  seeking  to  classify  genes  for  biomedical  applications.  These  divisions 
correspond to two scientific configurations around different referents, reflecting a vision of 
science  as  producer  of  academic  knowledge  versus  science  as  producer  of  economic  or 
applied use values. 
In order to link scientific advances to a development of biotechnologies, the uncertainties 
related to a new field, in terms of  knowledge, techniques, data management, funding, and 
ethical questions, had to be reduced through collective forms of organisation and institutional 
initiatives. The public authorities thus initiated a series of actions which served as both motors 
and  attempts  at  segmented  co-ordination,  interrelating  public  and  private  sectors.  These 
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1.1 The co-ordination of public and private research activity to create an S&T space 
 
The construction of the first genetic map of the human genome corresponded to a specific 
configuration of players (designers, producers, users) that gave rise to its own innovation 
dynamic  in  international  competition.  This  configuration  was  largely  stimulated  on  by  a 
private player in the non-profit sector. 
 
1.1.1  The driving role of the private non-profit sector 
 
 An original feature of French medical research relative to the general organisation of the 
country's research is the role of  foundations and non-profit organisations which mobilise 
private resources (e.g., for the Institut Pasteur or the Institut Curie). Their presence serves to 
modify  science-State  relations.  In  this  context,  genomics,  emerging  from  a  new    techno-
scientific field based on genetic engineering and biotechnologies, was the fruit of the decisive 
impetus of two private structures, the Centre d'Etudes sur le Polymorphisme Humain (Centre 
for  Research  on  Human  Polymorphism,  CEPH)  and  the  Association  Française  contre  les 
Myopathies (French Neuromuscular Distrophy Association, AFM).  
 
The CEPH  was a private laboratory set up by a foundation in 1983; as such, it defined its own 
rules of operation and personnel hiring, but as of 1988, it was funded by a direct budget line 
from the Ministry of Research. From an organisational standpoint, the CEPH constitutes a 
double breakthrough. In terms of research, it breaks with the artisanal practices of French 
research teams. Its investment in a massive, technological, semi-industrial approach depends 
on funding for operations and equipment that is three to four times higher than that of a classic 
laboratory of the same size. From the management standpoint, its private status, which allows 
it to hire personnel without the constraints faced by public institutions like INSERM or the 
CNRS, make it an atypical structure enjoying research conditions close to those prevailing in 
the United States. From the standpoint of the micro-foundations of the technological evolution 
of sequencing, which extends to its present industrialisation, this double feature allowed the 
CEPH to situate itself in an essential segment.  
The AFM is a non-profit organisation founded in 1958 to work for the curing of hereditary 
neuromuscular diseases. AFM's activities fall into three domains: collection and management 
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of  the  State  concerning  research  on  genetic  diseases,  AFM  decided  to  provide  financial 
support in this area.  Since 1988, its scientific policy has covered the entire spectrum, from 
clinical to therapeutic to genetic research, with a combination of long- and short-term projects, 
exploration and application, in short, every activity likely to contribute to the development of 
treatments. Along with its scientific programmes, the AFM's laboratory, the Généthon, had 
two development programmes in computer science and technology.  
 
United by common interests, the joint activities of the CEPH and the AFM set out the main 
significant  parametres  of  genomics  in  France,  a  crossroads  between  academic  scientific 
research and industrial applications, and related biotechnologies. Their appeal to the public 
authorities to create a dynamic by initiating path-breaking scientific or technical programmes 
perpetuated this  existence and gave rise to  the main dimensions  of a new scientific and 
technical space permitting complementary interventions by the public authorities, public and 
private research bodies, industries and hospital institutions. In 1992, Généthon's publication of 
the physical and genetic maps of the human genome placed French genomics in the forefront 
in face of international competition. The success of genomics through the initiatives of the 
AFM, "government partner," led the public authorities to take over for the association on 
issues  that  the  latter  considered  to  be  of  collective  interest,  such  as  the  localisation  and 
identification of genes, and to follow in its footsteps by investing heavily in mapping and 
sequencing. 
 
The AFM's schemes contributed more to creating a research field that was well endowed 
financially and technologically and that brought together different skills around genomics than 
to  shifting  the  orientations  of  public  research.  They  thus  exerted  a  "lever  effect"  on  the 
existing scientific structure, mobilising a high-level academic potential and giving rise to a 
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1.1.2  Co-ordination  mechanisms  between  public  research  bodies  :  scientific  and 
technical dynamics and institutional inertias 
 
The  CEPH  and  Généthon  had  opened  up  a  scientific  field  by  means  of  one  technology, 
massive sequencing; the public co-ordinating mechanism was responsible for anchoring this 
technology  in  a  specific  context  (a  segmented  scientific  community)  by  creating  an 
institutional framework structuring this community around shared objectives. 
In order to meet this need, the public authorities set up the Groupement de Recherches et 
d'Etudes sur les Génômes (Genome Research Group, GREG), which was given the double 
responsibility of distributing public resources and developping forms of supervision for the 
scientific  and  technical  activity.  Created  in  1993  in  the  midsts  of  the  scientific  (and 
governmental) cleavages around the controversy over whether or not to join the international 
genome programme, the GREG, which brought together the Ministry of Research and the 
major  public  research  institutions  (CNRS,  INSERM,  CEA,  INRA,  INRIA),  marked  the 
culmination of a period of political non-decisions. It was thus an institutional compromise, a 
stabilisation of contradictory rationales, following an expert's report establishing the benefits--
scientific, technological, economic, commercial and training-related--that might be expected 
of  such  a  project,    at  a  time  when  Anglo-American  research,  supported  by  national 
programmes, was taking a decisive lead. 
 
The effort at structuring and co-ordinating the genomics research community focussed on  the 
development  of  technological  advances  in  the  area  of  systematic  analysis  of  DNA  and 
genomes  (automation,  identification,  marking,  separation),  the  development  of  the 
bioinformatics services that are essential to genome research and training activities to improve 
the skills level of GREG's partners in bioinformatics and turn out researchers with double 
specialities in information science and genetics. 
 
Through the resources allocated to it, GREG had the effect of displacing a certain number of 
teams  towards  a  field  between  the  genome  and  medical  genetics,  which  gave  them  a 
respectable position internationally and allowed them to benefit from the consequences of 
Généthon's mapping and advances. It defined the contours of a scientific community at the 
intersection of fields of common interests, but this community remained fragmented, without 
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Observing the absence of a significant technological breakthrough for the study of genomes, 
GREG set itself the task of compensating for this deficiency by making projects offering real 
technological  innovations  its  priority.  Indeed,  the  analysis  of  the  low  funding  level  of 
technological research (excluding computer science) between 1988 and 1993 showed a near-
total  absence  of  projects  emanating  from  French SMEs,  with  the exception of the Bertin 
Company's  Labimap  project.  But,  for  lack  of  proposals  of  adequate  quality,  technologies 
represented only 6 percent of its funding. Suspended after three years under pressure from the 
AFM, which, in its dealing with the Ministry, advocated a transfer of academic knowledge 
towards semi-industrial projects, its action was very short term and thus not determinant. 
 
The juxtaposition and simultaneity of the mechanisms for co-ordinating public activity with 
the  AFM  on  the  one  hand  and  the  GREG  on  the  other  gave  rise  to  an  institutional 
segmentation  of  scientific  policies  for  the life sciences  and the scientific field  in  biology 
between medical genetics and genome research, the effects of which were negative for both 
scientific co-operation and the creation of biotechnologies.  The mechanisms for incentives 
and co-ordination did not function consistently enough to create common rules and norms that 
might  provide  public  action  guidelines  for  supervising  collective  scientific  and  technical 
activity.  Institutional  inertias  and  an  uncertain  legal  environment  thus  encumbered  the 
institutionalisation of a potentially innovative scientific and technical space. 
 
1.2 Difficulties in setting up a space for innovation in biotechnologies  
 
The  first  CNRS  document  offering  a  forward-looking  vision  of  biology,  Biologie  1990  - 
Enjeux et problematiques (Biology 1990 - Issues and problematics, 1987), assigned biological 
research four major issues for the society: health, the food-processing industry, the use of 
micro-organisms and the environment. 
Given these requisites for scientific research, we shall examine the ways that the scientific and 
technical space for genomics was opened to the medical and industrial sectors interconnected 
by biotechnologies, as well as the obstacles to such a development. Indeed, the institutional 
mechanisms  that  were  put  in  place  partly  determined  the  way  relations  were  organised 
between research and industry, and their interactions during this period. Through the new 
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sharp accentuation of science-industry integration and the production dynamic of the new 
technologies arising from the encounter of the knowledge  mobilised and innovative players. 
But they came up against the potential constraints of the national institutional frameworks--the 
financial, legal and training systems. 
 
1.2.1  Support mechanisms for opening the scientific and technical space of genomics to 
innovation 
 
The opening up of the S&T arena to partnerships likely to transform scientific discoveries into 
economic  or  social  values  depended  on  public  institutional  mechanisms,  and  the  AFM's 
strategies. 
 
1.2.1.1   Institutional mechanisms for partnership between public research bodies and 
industrial research 
 
In  typical  fashion  within  the  hierarchical  functioning  of  French  schemes,  incentive 
programmes were set up at the initiative of the Ministry, along with actions proper to the 
public research bodies. 
 
Biotechnologies have been the focus of national programmes in France since the beginning of 
the 1980s: the kick-off "Essor des  biotechnologies" ( Biotechnologies expansion) programme 
in  1982,  the  Biotechnologies  National  Programme  in  1985,  "Sauts  technologiques" 
(Technological leaps) in 1988, the Bioavenir (Biofuture) programme in 1992. Developped by 
the Ministry of Industry's Research and Technology Fund (FRT) and the Ministry of Research, 
they were eleborated in different departments of the CNRS with a double objective: 
  Encouraging researchers to envision, and if need be develop the results of their work 
applicable in the short term, in the form of technological spin-offs ; 
  Working  for  the  development  of  fundamental  research  upstream  from  the 
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The idea was thus to favour the applicability of research in order to reinforce links between 
scientific research and the creation of technologies for public or industrial research, followed 
by the emergence of small biotechnologies companies.  
In  fact,  this  programme,  carried  out  in  the  form  of  Actions  Thématiques  Programmées 
(Programmed  thematic  activities,  ATP)  lasting  two  years,  suffered  from  increasingly  low 
funding (10 million francs  for two years in 1983 ; 2.4 million francs in 1988) and had poor 
implementation (13 to 27 contracts per year). 
 
As  for  the  Bioavenir  programme  (1992-1997),  initiated  by  the  Minister  of  Research  (H. 
Curien), it was originally presented as a model of  co-ordination between public and private 
research, in terms of its scope, its duration and its wide-ranging mission. Supported by the 
public authorities (Ministries of Research and Industry), it involved the main public research 
bodies (CEA, CNRS, INRA, INSERM, Institut Pasteur, universities) in a collaboration with 
one quasi-exclusive industrial partner, Rhône-Poulenc. With a budget of 1.6 billion francs (1 
billion from Rhône-Poulenc and  610 million from the Ministries), it was intended to ensure 
the  mobilisation  of  skills  and  means  at  the  interface  of  life  sciences  and  chemistry  and 
strengthen  collaborations  in  order  to  accelerate  the  transfer  of  knowledge  between 
fundamental research and applied or industrial research. But more specifically, for Rhône-
Poulenc,  the  idea  was  to  invest  far  upstream  on  fundamental  research,  to  identify  and 
characterise new biological targets in order to take advantage of the most recent developments 
in molecular biology and genetics and to adopt a rational conception in the elaboration of new 
active  compounds  by  "generating  the  skills  needed  to  overcome  identified  technological 
barriers." 
For the public research bodies, and the CNRS in particular, the rapprochement of research 
with  industry  came  under  a  certain  number  of  programme  activities  initiated  by  its  Life 
Sciences Department (DSV) : 
  Cross-disciplinary research programmes, which involved several CNRS departments and 
developped interfaces with industry.  
  One ATIPE programme (Actions thematiques incitatives sur programmes et équipes : 
Thematic activities providing incentives for programmes and teams). Between 1990 and 
1994, the ATIPE programmes led to the constitution of 32 new teams at the DSV/CNRS. 
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1.2.1.2   Mobilisation of the AFM for the involvement of industrial support 
 
As of 1994, the AFM refocussed its activity on gene therapy. This reorientation  made it 
necessary for the association to acquire an industrial backing capable of creating a market to 
make the large-scale development of these therapies viable. The AFM relied on a double 
strategy. On the one hand, it signed co-ordination agreements with biotechnologies firms, 
once  it  had  organised  concerted  actions  to  generate  innovation  by  combining  specific 
complementary  assets  (with  the  AFM  monitoring  the  patients'  genes).  For  the  small 
companies  in  biotechnologies,  the  contribution  of  the  patients'  associations  provided  an 
incentive to involve themselves the field of gene therapy, through long and costly investments, 
through the close collaboration with clinicians and the implementation of the therapy (the co-
operation of the patients), through the co-ordination of complementary assets to bring together 
varied knowledge and know-how (setting up a technological basis, co-ordination of research 
centres in vectorology and gene therapy centres, etc.), which were subsequently to allow the 
companies to transfer acquired competences on rare diseases in order to enter the sought-after 
mass markets.  The AFM thus signed agreements, first with Transgène, then Genset, and 
finally Rhône-Poulenc. This was to give rise to the problem of the private appropriation of 
externalities produced through co-operation: the AFM ultimately registered patents on the 
genetic disease genes discovered in order to protect the pharmaceutical industry's exploitation 
rights.  
 
Furthermore, alongside its co-ordination activities intended to modify research practices, by 
initiating ties between research teams funded by the association and industry, relations which 
were to be perpetuated over time, the AFM sought to influence the public authorities so that 
the latter would attract to the field of gene therapies the industrial skills likely to create  a 
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1.2.2  Obstacles arising from the institutional frameworks 
 
These obstacles originate, on the one hand, from institutional factors of management and 
supervision  specific  to  the  biomedical  sector  and,  on  the  other,  from  the  specific  French 
configuration of the national system of innovation. 
 
1.2.2.1  The impact of the legal framework on the science-industry relationship in the 
biomedical field 
 
The factors that might be detrimental to the development of the French industrial structure in 
the  context  of  international  competitiveness  lie  first  of  all  in  the  cumbersomeness  and 
complexity of procedures for the supervision of research and experimentation, and second in 
the uncertainties of the legal framework for this research-industry interaction. 
 
In the area of biomedical research and clinical experimentation in therapeutic biotechnology 
firms, which involves the notion of the "genetically modified organism", the much greater 
national research effort required in order to go beyond the phase of clinical trials was blocked 
by the abundance of regulations and inconsistency of texts, as well as the intervention of 
multiple supervisory institutions. This institutional apparatus and proliferation of procedures, 
which created a veritable obstacle course  for those requesting trials, proved to be largely 
dissuasive. Companies of sufficiently large size (e.g., Transgène) relocated their trials outside 
of France.  
 
In  the  area of  intellectual property rights, the organisation of closer interactions  between 
public research and industry suffered from the constraints imposed by the acuteness of the 
ethical problems raised, as well as a context of dispersed, if not framented industrial property. 
Indeed, this situation raises the problem of the legal protection of biotechnical inventions 
and the patentability of the elements and products of the human body, insofar as the latter 
constitute, for the moment, the essential source of "raw material" for biomedical research and 
industry. 
In the United States, the need to describe the new function of the genetic sequence claimed as 
an "invention" led to a maximum of anticipation, with requests for the protection of the widest 
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the principles established by the changing technical practices of the European Patents Office 
until July 1998, when the draft directive of 1988 was  definitively adopted. 
 
European patent law thus became more homogeneous by successive steps in the direction of a 
technique-based law permitting greater interaction between research and industry. 
But during the entire debate over the community directive, which coincided with the first 
phase studied here, the biotechnologies players came up against the uncertainty of the legal 
framework. 
 
The status of the procedures and products of gene therapy has also constituted an obstacle to 
the development of the biomedical industry in France.  
Gene therapy involves procedures that must meet norms on medical devices (e.g., quality 
controls and insurance). In this area, the singular nature of the French institutional mechanism 
within the European Union, which aroused the opposition of the SMEs in the biomedical 
sector until 1995, penalised biomedical R&D and weakened existing ties between research 
and industry in France. It thus led the French biomedical industry either to abandon research 
projects  or  to  relocate  clinical  trials  and  the  manufacture  of  medical  devices  outside  the 
country. This particular feature only came to an end with the application of the European 
system  (CE  marking  rules  since  1998),  which  improves  upon  the  previous  French  legal 
framework. 
 
With regard to the products of gene therapy, their status (drug or other) still remains uncertain. 
Such a definition is important for the distribution of negotiating powers and forms of co-
ordination  between  the  different  players  in  research,  health  institutions  and  industry. 
Uncertainty over the development of these products, and the conditions of sharing the results 
of scientific inventions can play a dissuasive role in industrial development and influence firm 
strategies.  
 
The economic incentives of government action in France over the period studied seem to have 
been too little and too late to encourage co-operation by giving rise to the creation of small 









































6    13 
1.2.2.2  The impact of other institutional forms of the national innovation system 
 
Two "societal" forms can be identified here, one arising from the financial system, the other 
from the educational and professional dimension. 
On the first point, the financial, fiscal or legal obstacles to the creation of start-ups that are 
most often cited include : 
  The  disadvantageous  tax  status  of  stock  options  issued  by  the  new  biotechnologies 
companies ; 
  the questioning of immediate restoration of the research tax credit for the new high-
technology companies ; 
  the absence of a system of  appropriate funding, start-up funds and venture capital ; 
  inadequate registering of patents by public research bodies with exclusive licenses for 
small enterprises. (In fact, venture capital only invests in patented technologies, and the 
competitors register patents.) 
 
Unlike other countries, moreover, there is no satisfactory legal solution for the establishment 
of  consortiums  bringing  together  small  and  large  companies  and  laboratories  for  the 
development of joint technological resources or co-operative research centres. 
The relevance of some of these arguments is, however, open to question. Concerning the lack 
of funding, even if, out of the two hundred investment companies in France, less than a dozen 
invest in start-up technologies, there were, besides the ANVAR, French venture-capital funds 
with growing assets. In 1995, biotechnologies concentrated 15 percent of venture capital (174 
million F) in France, and the medical-healthcare sector, 18 percent (260 million F) (Source: 











Figure 5 : Venture capital investment in biotechnology 
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Thus, the bottleneck is not to be  found in the financial resources. For Pascal Brandys,  
president of Genset, "The main obstacle to the creation of  biotechnologies companies remains 
the lack of quality entrepreneurs". 
In the educational and professional sphere, the obstacles identified include : 
  a rigid definition of the researcher's status, which excludes any participation in the capital 
of a start-up and would create difficult conditions of return to the original public research 
institution ;  
  the absence of interrelated scientific and entrepreneurial training programmes.  
 
In  fact,  the  main  obstacles  seem  to  arise  from  specific  practices  of  the  public-sector 
researchers, who aspire to an academic scientific career where criteria for success and the 
corresponding  incentives  are  established  within  a  scientific  community  fashioned  for  the 
production of scientific knowledge according to a dominant "order". Technological research 
remains  little  developped  because  it  does  not  advance  a  researcher's  career,  nor  does  it 
contribute to advancement in industry or mobility towards the companies. As a result, public-
sector researchers, who are the privileged intermediaries of closer ties between the S&T and 
industrial  spaces,  through  the  transfer  of  ideas,  skills  and  technologies,  enjoy  very  little 
mobility towards the companies. It is symptomatic that the qualitative leap made in France 
through the introduction of large-scale sequencing techniques came from a private laboratory 
(Généthon) and was viewed amongst biologists as a "technological excess" to be associated 
with development rather than research. 
 
1.2.3  Little  efficiency  in  terms  of  technological  performances,  innovation  and 
competitiveness 
 
Beyond  the  rhetoric  developped  by  the  scientific  units  of  the  S§T  institutions  about  the 
opening  up  of  research  to  the  socio-economic  players  and  the  strengthening  of  industrial 
partnerships,  the  results  of  the  interaction  of  French  institutional  arrangements  for  the 
development of ties between life-sciences research and economic performances, technological 
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According to OST 2data, France's position is better on the scientific level (publications rating) 
than on the technological level. This gap can be illustrated through three indicators: patents, 
contractual relations between public research bodies and companies and  the creation of 
companies on the basis of scientific potential. 
 
On terms of patents, the same decline can be observed in biotechnology as in other fields, with 
the result that France accounted for only 6.4 percent of European patents in 1996 (6.6 % for 
the  pharmaceutical  industry).  For  American  patents,  the  decline  was  less  pronounced  in 
biotechnologies and the pharmaceutical sector (5.1 %), reflecting the implantation of French 
firms  in  the  United  States  during  that  period,  through  the  creation  of  subsidiaries  or  the 
acquisition of American companies. In all, biotechnologies represented 2.9 percent of French 
and European patents and international patents designating France in 1996. 
 
In  a  context  of  limited  co-operation  between  public  research  bodies  and  business,  the 
particular features of relations between academic research and companies in the life sciences 
can be identified (cf. Table). According to the White Paper on R&D co-operation between 
industry  and  the  public  sector  published  by  the  Syndicat  National  des  Industries 
Pharmaceutiques  in  1997,  network  relations  function  with  INSERM  and  the  university 
hospital sector on collaborations for clinical research. At the CNRS and in the universities, 
interface  structures  aimed  at  optimising  relations  with  industry  are  insufficient,  or  overly 
centralised. When the rationales of the two kinds of partners do not converge--which is most 
often the case--no attempt is made to bring them closer in order to formalise the mutual 
benefits of a long-term collaboration. 
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Relations :  industries life sciences – public organisms 
 
Organisms￿   Research Services￿   Contracts￿   Outlook for Industry￿  
CEA￿   -  synthesis  of  biological  molecules  by  stable  and 
radioactive isotopes 
-  pharmacological  and  pharmacokinetic  studies  for 
preparation of AMM reports 
-  validation  of  bioindustrial  processes  for  their 
capacity to destroy unconventional infectious agents 
(prions) 
114 contracts in 1994 : 45 % for collaboration 
(average  length  :  2  years),  5  %  research 
services 
Total amount : 32 million F 
(RP-Rorer, Sanofi, P. Fabre, Servier, Biotech, 
Orion, Glaxo, Basf, Roussel-Uclaf, Transgène) 
The CEA wants to be more officially involved 
in industry's decision-making bodies. 
Industry has the same desire, with the hope that 
this  involvement  will  be  reflected  in  the 
laboratory experiences.   
INSERM￿   -  delegated  research  (exploratory  phase, 
pharmacological  targets,  molecular  screening), 
financed by industry 
- shared research (new medications) 
- integrated team 
- research services 
Unavailable  Need for more profound collaboration. 
Reciprocal recognition of diplomas facilitating 
both mobilities and careers via mixed jobs. 
CNRS￿   -  5  mixed  research  units  in  direct  relation  with 
industry 
- framework agreements with individual contracts 
-  participation  of  Life  Sciences  Dept.  in  Bioavenir 
programme 
- short-term contracts 
- human resources support 
The CNRS prefers the formula of mixed units 
over research contracts 
Favouring  closer  ties  between  public  units 
through the development of unifying themes. 
Reciprocal recognition of diplomas facilitating 
mobilities and careers via mixed jobs.  
Universities￿   20 post-graduate diplomas (DEAs) in "medications" 
fields including: 
- pharmacologically active substances 
- evaluation of medications and xenobiotics 
- pharmaceutical legislation 
Unavailable  Improved  visibility  of  research  training 
programmes. 
Integration  and  organisation  of  doctoral 
programmes. 
Encouragement of mobility (review of status). 
Pasteur￿   -  bacteriology  and  mycology￿ -  virology￿ - 
biochemistry  and  molecular  genetics￿ - 
biotechnologies￿  
The  office  of  development  and  industrial 
relations ensures the transfer of results from the 
units  towards  the  industries  (22  million  F                          
for  expertise  in  1994,  5  million  F  in  R&D 
contracts,  200 million F in licensing fees paid 
to the institute. 
Opening  up  the  institute's  collaborations  (two 
privileged partners : Sanofi Diagnostic Pasteur, 
Pasteur Mérieux Sérums et Vaccins) 








































6    17 
This  situation  explains  why  all  the  technological  methods  of  molecular  biology  were 
developped in the United States and Great Britain, with French researchers depending on US 
companies or their English subsidiaries  (Molecular Dynamics, Amersham) for 80 percent of 
the equipment and reagents used, as well as for computer software. France now has to  make 
up  for  its  backwardness  in  platform  technologies.  Scientific  advances  in  vectorology  in 
France, for example, have not given rise to the creation of companies. The most revealing 
recent example is that of the technological change in DNA chips, which, spreading through 
their miniaturisation, were to revolutionise sequencing and detection of pathologies. This shift 
could have been taken place in France at the beginning of the 1990s (the skills existed), but 
the idea was exploited by the California company Affymetrix. 
Similarly, research in gene therapy was deemed "rather well developped" in France in the 
SDV economic report of 1992, with several  first-rate teams on the international level, but the 
lack of ties with the pharmaceutical industry slowed down the development of the necessary 
biotechnologies.  In  mid  1996,  there  were  a  few  dozen  patients  being  tested  in  France, 
compared to 1,230 in the United States, 61 in Great Britain, 55 in the Netherlands and 47 in 
Germany.  
 
The creation of businesses has thus remained slight, while biotechnology is a sector where 
innovation emerges above all from small companies, whose creation is closely tied to the 
institutional system. In terms of performance, Europe's lag in 1996 relative  to the United 
States in the area of biotechnologies companies was patent (716 companies, employing 27,500 
individuals, compared to 1,287 in the United States with 118,000 employees, according to 
Ernst & Young), but the industry was getting off the ground. France, however, wound up in 
third place in 1997, behind Great Britain and Germany, countries where recent changes in 
legislation and the commitment of public authorities have given rise to the doubling of the 
number of companies every year since 1996. In France in 1996, fewer than fifty start-ups had  
arisen from research spin-offs, often with ANVAR's aid for innovative projects. Several of 
these have risen to world rank (Genset, the first to have been rated on the new market and 
NASDAQ  in  1996,  Cerep,  Flamel  Technologies,  IDM,  Appligène,  Oncor,  Transgène, 
Genopoïetic, Chemunex, Biovector Therapeutics). But with the patrimonial rationale winning 
out over the entrepreneurial one, few small companies coming out of the academic world 
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research on monoclonal antibodies, managed to place itself on the market but was bought out 
by the American Coulter group in 1995, under pressure from venture capital companies.  
 
Following the collapse of funding from venture capital companies and investment funds after 
1992, the strategies of companies specialised in biotechnologies (CSBs), consisted to forming 
multiple alliances with the major pharmaceutical groups. For more than twenty years, the 
biotechnology products sector has been dominated by the US industry, which held 90 percent 
of the world market in 1996. Two-thirds of these markets are oriented towards therapeutic and 
diagnostic products. After the first generation of biomedications resulting from genomics--
human proteins with therapeutic functions, the sale of which in the United States represented 
nearly 25 billion francs in 1994--a second generation emerged from the effects of sequencing 
and the isolation of genes implicated in diseases. In France, meanwhile, this potential market 
segment  saw  the  creation  of  partnerships  among  research  units,  biotechnology  companies 
involved in the identification of genes and regulatory regions associated with diseases and the 
pharmaceutical industry (with or without exclusive licenses), but these most often involved 
Anglo-American  partners.  Genset,  the  leading  French  genomics  company,  had  exclusive 
agreement protocols for a single disease with two pharmaceutical groups, Synthélabo and 
Johnson & Johnson. Génopoïetic developped gene therapy techniques on the basis of patents 
from  the  Institut  Pierre  et  Marie  Curie,  with  support  from  Rhône-Poulenc  for  product 
marketing.  And Transgène was essentially created with public and charitable funds and later, 
for a limited period, with support from Rhône-Poulenc (prior to agreements with HGS and 
Schering-Plough in 1998). 
 
In spite of government efforts for the funding of industrial R&D (according to the MENRT, 
public authorities allot over 10 billion francs annually to biological,  agricultural and medical 
research), two paradoxical elements emerge:  on the one hand, the French industrial fabric's 
low capacity for integrating the advances made in the S&T arena, and on the other, the know-
how of a small number of industrial groups for profiting from public funds and resources 
allotted to research transfers towards industry and the development of industrial research. 
On  the  first  point,  we  have  observed  the  inadequacies  of  industrial  development  of 
technological advances for research, notably the technological platforms. The second point 
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predominance of several large industrial groups as beneficiaries of technological policies and 
public subsidies for R&D. 
The  interministerial  Bioavenir  programme  (R&D  for  the  integration  of  concepts  and  
innovative  techniques  in  biology)  is  representative  of  the  French  policies  of  major 
technological  programmes  shaped  by  the  Colbertian  model  of  the  post-war  period.  It  has 
monopolised public funds instead of using them to encourage an industrial fabric of small 
biotechnology  companies,  and,  contrary  to  the  aims  of  an  umbrella  mechanism,  has 
compartmentalised its collaborations.  
 
1.3 Evaluation of the innovation dynamic of institutional frameworks for the 1985-1996 
period 
 
At the level of the scientific and technical system, several strategies for action have been 
superimposed, without necessarily resulting in convergence among them. 
The CEPH and AFM, which private structures, have played innovative roles by introducing 
semi-industrial scientific methods into molecular biology and developping molecular genetics. 
They  have  laid  down  the  foundations  for  a  new  scientific  and  technical  space and given 
France international standing in genomics. 
The GREG, as a framework for controversies, negotiations and elaboration of compromises 
between the different public Public S&T institutions and the university hospitals, was the 
prefiguration of an initial rapprochement of teams from different disciplines and outlooks. Its 
intermediary role permitted the initiation of a collective organisational learning process, but 
one that was limited to the scientific environment. It did not serve as a magnet for structuring 
a broader space around a clearly identified national genomics programme bringing science and 
industry into interaction.   
The  Bioavenir  programme,  meanwhile,  has  had  an  impact  on  the  socialisation  of  public 
researchers to industrial research by showing them that it was possible to conduct fundamental 
research on industrial preoccupations. 
For the educational and professional system, the consequences of the schemes for public-
private co-ordination  have been segmented and have not allowed the creation of a cross-
disciplinary  dimension  essential  to  this  zone  of  innovation,  with  a  "professional  space" 
transcending the fields and missions of the different public or private research institutions and 
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compartmentalisation between institutions, the inadequate hybridisation of disciplines (e.g. for 
bioinformatics),  and  the  tendency  towards  dispersal    of  the  means  of  sequencing  (or 
preclinical tests for gene therapy) in isolated sites of "artisanal" research have all slowed down 
a circulation of "contextualised" knowledge about the analysis of genomes, its socio-economic 
stakes and the technological means to be mobilised in order to participate internationally in 
the production of the data conditioning their utilisation. 
 
At the level of State action, the interventions of institutional players have been discontinuous 
and out of phase with the dynamic that globalisation has given to strategies of innovation and 
industrial diffusion in this field. France has not been the driving force at European level that 
its  scientific  base  might  have  permitted.  The  unsuitability  of the public S&T institutions' 
information tools, the sporadic nature of public action owing in particular to the political 
instability and tensions between the Ministry and the different public S&T institutions in the 
games of influence and competition amongst criteria (medical advances, genes of economic 
interest, etc.), the absence of any real evaluation of discontinuous schemes and inadequate 
procedural  training--the  characteristics  of  a  top-down  public  policy--ultimately  had  a 
disturbing influence on the creation of a space for innovation in genomics by a private player 
called upon to compensate for the failings of public action. 
 
The process of building this new field, genomics, thus remained fragmented, for lack of an 
institutional awareness that would have significantly changed the public authorities' forms of 
intervention.  This  sectoral  public  policy  has  in  fact  been  marked  by  a  "determinism"  of 
institutions shaped to meet objectives defined by post-war scientific and technological policies 
(Callon  and  Foray  1998).  Its  "mission-oriented  policy"  (Ergas  1994)  characterised  by  a 
centralisation of top-down decisions and a concentration of resource allocations on major 
programmes) has been juxtaposed with zones of non-decisions and dispersion over the new 
fields to develop in a science-innovation tandem. In addition, it has remained bound to the 
linear  model  of  innovation  that  goes  from  basic  research  to  applied  research  to  the 
development of products or services. In the French industrial environment of the 1985-1996 
period, it has thus generated low efficiency relative to the stakes of the mechanisms intended 
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2  INSTITUTIONAL REFORMS AFTER 1996 : THE INSPIRATION OF 
THE ANGLO-AMERICAN INNOVATION MODEL 
REAPPROPRIATED ON THE BASIS OF FRENCH INSTITUTIONAL 
FEATURES 
 
At the same time that the institutional structures, backed up by the major player that the State 
represents in France, were outlining the operation of private and public R&D activities in the 
area of genomics, certain institutional arrangements were modified under the impetus of other 
dynamics. Indeed, scientific and technological interdependencies and dissemination in terms 
of  the  globalisation  of  research  in  this  field  not  only  modified  basic  techniques,  and  in 
parallel, the organisational forms of the  different sectors involved, but had as its corollary the 
generalisation of an optimal "model" for the production of science and innovation. In France, 
this  model  had  the  concrete  effect  of  colliding  with  the  Colbertist  model  of the science-
innovation tandem but did not replace it, insofar as the overlaps themselves had structuring 
effects. 
 
2.1 An "ideal model" of coproduction of knowledge and science-industry interaction in 
biotechnologies 
 
2.1.1  Origin of the model 
 
Molecular biology developped in a transnational space, but its rapid rise is tied to the major 
role played by the United States and the significant investments allocated to its development 
by public bodies as a follow-up to funds previously provided by private bodies such as the 
California Institute of Technology or the Rockefeller Foundation (Morange 1995). 
With  the  spread  of  genetic  engineering  at  the  end  of  the  1970s,  contemporary  molecular 
biology became more technical and more oriented towards a development of its applications. 
Most of the projects and investments were concentrated in the United States. The accelerated 
growth of this techno-scientific field then amplified existing features of the development of 
the  sciences  after  the  Second  World  War.  Open-market  competition  became  an  essential 
criterion  for  political  and  economic  activity,  and  this  political  transformation  was 
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spaces with economic and/or social value and a growing interpenetration between academic 
knowledge and the search for efficiency. This evolution led to a phenomenon of hybridisation 
between scientific, technical, industrial and financial activities, depending on particular modes 
of production and transfer of knowledge, in scientific-industrial concentrations exemplified by 
Silicon Valley or Route 128. 
 
The emergence of this "new" regime for the production of knowledge has been described by 
Gibbons in positive terms for the stakes of political action, economic dynamics and scientific 
development ("The New Production of Knowledge, the Dynamics of Science and Research in 
Contemporary Societies" in Gibbons et al 1994). In the academic literature, it became known 
as the "Triple Helix model", advanced notably by Etzkowitz and Leydesdorff (1997).  
According  to  this  model,  the  locus  of  what  now  evolves  towards  a  "coproduction"  of 
knowledge  is  situated  at  the  intersection  of  three  interacting    institutional  spheres:  the 
university  and  the  research  bodies,  industry  and  the  public  authorities.  The  aim  of  this 
interrelationship  is  to  develop  research  capacities  and  a  transfer  of  economically  relevant 
knowledge to industry by integrating the research infrastructures in the innovation systems. 
The underlying hypothesis of such an approach is that the economic dynamic is now based on 
the development of generic knowledge and its diffusion within the fabric of the production 
apparatus. In this setup, the interventions of the public authorities should thus tend to favour a 
virtuous  spiral  between  the  multiple  linkages  of  cross-over  networks  that  emerge  at  the 
different  stages  of  the  innovation  process.  By  formulating  policies  and  programmes 
encouraging strategic alliances between companies and research organisations, the creation of 
spin-off  firms,  the  implantation  of  R&D  structures  transcending  traditional  institutional 
borders  (public-private,  academic-applied,  etc.),  the  founding  of  scientific  and  industrial 
concentrations  at  the  local  level,  and  so  on,    these  public  interventions  would  follow  a 
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2.1.2  Transfer of the "model": adoption as a normative system and reinterpretation 
according to each country's specific institutional contexts 
 
The discourses related to this model were linked to expanding practices of research production 
that were nonetheless tied to the institutional context of the United States. These practices 
were transformed into a normative system on the basis of the shared representations made by 
the institutional players, and this system was then drawn upon in order to create new shared 
socio-cognitive guidelines for public action, as criteria for updated forms of action but with 
different kinds of appropriation depending on the European countries involved. It was spread 
largely  through  experts'  reports  and  programme  activities,  mainly  those  of  the  European 
Commission. Interaction with R&D at international level and competition/co-operation with 
other  systems  of research and innovation  gave rise, at  the European level  of institutional 
support, to the diffusion of scientific advances and techniques, the standardisation of tools and 
procedures,  the  modification  of  guidelines  for  the  science-innovation  relationship  and  the 
aligning of European intellectual property law with American law in the biotechnologies field. 
Given  the  not  inconsiderable  volume  of  funding  provided  by  the  European  programmes 
relative  to  French  budgets  for  research  or  technological  development  outside  the  major 
programmes, the impetus provided by the European dynamic could help to restructure the 
functioning of public and private research in France. In particular, the emphasis placed on co-
operation that is not only transnational but also transdisciplinary and transorganisational (in 
the sense of a greater integration between science and industry), as well as the replacement of 
a rationale of funding alone by one of incentives centralised at European level, which are the 
priorities  of  Community  action,  seek  to  strengthen  the  bases  of  a  mode  of  research 
organisation that is more open to economic applications (multiplication of partnerships and 
dialogue between decompartmentalised fields of research and action). The latter is considered 
more efficient according to the current requirements of international competitiveness. The 
quantitative  extension  of  the  practices  privileged  by  these  programmes  could  lead  to  a 
qualitative change in the overall research system. Beyond stimulating the dissemination of 
knowledge  between  member  countries,  these  policies  tend  in  fact  towards  effects  of 
normalisation  in  the  production  of  knowledge  and  the  creation  of  technological  and 
organisational standards that can be linked to the diffusion of the updated "model" of the 
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Such irreversible processes and the disruption of representations in France are bringing about 
an endogenous societal reaction of adjustment to the globalised environment, a change in the 
guidelines and the forms of public action. This results in an institutional dynamic consistent 
with the scientific and technical dynamic, and the creation of conditions at local, national and 
international  levels  that  allow  "transforming  research  results  into  economic  and  social 
innovation". 
 
2.2  The beginnings of new forms of public intervention ("diffusion-oriented policy") 
  
At the level of State action, a certain number of programmes and new measures, of general or 
particular scope, have permitted the introduction of new strategies for action by removing 
legal obstacles and created conditions for the development of  small innovative enterprises 
through the shift from a patrimonial to an entrepreneurial rationale.  
 
2.2.1  Innovation-promoting changes in the institutional environment   
 
The law on innnovation of July 1999  was explicitly aimed at bringing public research and 
companies closer together in order to "increase the capacity for innovation and the creation of 
wealth". It allows for several forms of incentives : 
  The elimination of statutory restrictions on researchers' mobility, allowing them to create 
a company on the basis of their studies without definitively leaving public research, or  to 
contribute  their  expertise  or  their  participation  in  the  capital  of  a  company  while 
maintaining their posts. 
  The  creation  of  structures  favouring  the  emergence  of  innovative  small  enterprises, 
notably  spin-offs  from  research  institutions  or  universities:  incubators  offering  an 
implantation site but  also  technical  support and legal and financial advice, and  seed-
capital funds to facilitate the first stage of creation, with State funding leading to calls 
for projects as well as a competition for aid in the creation of innovative technological 
enterprises. 
  The  institution  of  a  fiscal  context  favourable  to  subscription  funds  for  shares  in  the 
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in  innovation  (FCPI).  The  tax  system  for  stock  options  remains  largely  dissuasive, 
however. 
  The  inclusion  of  innovative  small  enterprises  in  a  legal  framework  that  is  more 
appropriate to them: the simplified stock company (société par actions simplifiée, SAS), 
which facilitates calls for investors and venture capitalists. 
 
In terms of the financial system, a positive change emerged with the creation of the New 
Market and EASDAQ, allowing high-tech companies  to be rated on the stock market. This 
trend was accentuated by the State's creation of a public venture-capital fund of 1 billion 
francs which, through the lever effect, allowed several times this amount to be raised amongst 
institutional investors, banks or local communities. 
 
2.2.2  A  new  technological  policy  for  the  biotechnologies  :  bridging  between  public 
research and biotechnologies  
 
Since  1996,  the  life  sciences  and  biotechnologies  have  been  made  priorities  for 
interministerial governmental action, in order to strengthen France's position on an essential 
strategical  issue  for  growth  and  employment.  A  second  Biotechnologies  Programme  was 
undertaken for five years, with joint public-private funding of 1 billion francs following calls 
for proposals. Its objectives are to stimulate collaborations between public laboratories and 
SMEs, to aid in the development of innovative principles or procedures (with the goal of 
tripling the number of international patents registered by the French), to favour the emergence 
of several thousand CSBs in order to create four hundred stable high-tech companies and set 
up new biotechnologies sectors that create jobs. 
In 1998, the Ministry of Research, which is empowered to intervene in industrial support for 
research, launched appeals to promote actions between public research and SMEs along two 
main lines: transfers in biotechnologies, where the large majority of the projects selected deal 
with  health  (genomics,  diagnosis  and  gene  and  cell  therapy),  and  health  technologies 
(instrumentation,  imaging,  bioinformatics).  In  1999,  funding  incentives  were  focussed  on 
programmes  dealing  with  the  extension  of  human  genome  sequencing  and  targetting 
therapeutic security and new treatments, functional genomics and biomaterials. The Ministry 
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bio-industrial tracks related to predictive, preventive and therapeutic medecine and thus giving 
rise to a partnership between public research, small biotechnologies industrialists providing 
technologies and services and applications CSBs. 
 
Apart from  incentive-providing grants,  the State's  impetus  is  now channeled in two main 
directions. The first involves the creation of genomics infrastructures: major facilities like the 
Centre National de Séquençage (which has a public budget of 80 million francs for ten years), 
the Centre National de Génotypage (50 million francs annually), the Centre de Ressources 
Informatiques Infobiogen and the Centre de Ressources for DNA collections, along with the 
development  of  national  networks  of  genomic  bioinformatics  and  genopoles.  The  second 
involves umbrella research programmes.   
 
The  most  state-led  ministerial  scheme  for  bringing  together  in  one  site  research  (public, 
private,  industrial),  small  enterprises  in  the  making,  experienced  CSBs,  industry  and  the 
university is the genopole for genomics and biotechnologies implanted in Evry in 1998. The 
idea is to develop a European-level pole of some sixty biotechnologies companies around the 
massive facilities of the CNS, CNG, and AFM laboratories by drawing on the results of public 
research, the installation of new companies in incubators and the synergy amongst research, 
technological  platforms  and  industry.  The  project  enjoys  support  from  the  major  public 
players  (State,  public  S&T  institutions)  and  regional  and  local  authorities,  as  well  as  the 
presence of experienced private players such as the AFM, Genset and Rhône-Poulenc-Rorer's 
Core Genomics Centre. 
 
It is clear that the structural elements of the national system of innovation have been modified 
and that new forms of public intervention, inspired by "diffusion-oriented policy" in their 
principles, aim to meet the new historical objectives by replacing the Colbertian model with 
more diversified and decentralised conditions of innovation spread throughout the economic 
and social fabric. Through the multiplication of partnerships, these allow for different fields of 
application (agricultural and agro-industrial, pharmaceutical, medical, environmental) where 
the generic products of genomic research can be accommodated. They also seek to favour the 
strategy of incentives over that of grants in order to reinforce the fluidity of the science-









































6    27 
 
2.3  The adaptation of the science-innovation pattern to the French institutional 
context 
 
In concrete terms, the new institutional arrangements have to remain functionally compatible 
with the overall configuration of research, industry and public intervention as it has been 
historically defined. This means that in France, the adjustment to the "model" is subject to 
transposition in its application and obstacles in the necessary collaboration of its different 
partners. 
 
2.3.1  Transposition of the application 
 
The emphasis of State action on procedures such as calls for projects or competitions, which 
tend to stimulate the main players of biotechnological innovation, destabilises the top-down 
organisational coherence of earlier technological policies, which was guided by an efficiency 
specific to the implementation of major national programmes. The result is a combination of 
contradictory elements in the functioning of these procedures, through the preservation of 
centralised  decision-making  and  top-down  management  in  schemes  initially  designed  for 
scientific and technical diffusion at the base. Thus, State funding is tied to a "seal of approval" 
bestowed  on  the  incubators,  genopoles  and  technological  platforms  by  the  Ministry  of 
Research,  which  defines  their  key  players  and  operational  features.  Networks  are 
predetermined  at  a  national  scale,  with  certain  cities  "chosen"  in  an  initial  phase  of  the 
scheme: the genopole network is supposed to be federated around the Evry Genopole, deemed 
to be the "network head", like a "national champion" serving as the public authorities' sectoral 
interlocutor. These attempts at supervision run counter to the organisational configurations 
emerging  locally  at  the  initiative  of  the  key  players  in  innovation  (the  "intermediate 
institutions"  of  transfer),  often  with  the  support  and  involvement  of  local  and  regional 
authorities.  The  incentive-providing  actions  become  focussed  on  forms  of  co-ordination 
imposed by a "mission" where the State would once again replace the localised autonomous 
initiatives of the public and private players without giving the different biotechnopoles the 
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2.3.2  Limitations owing to the configuration of the French pharmaceutical industry : 
inadequate industrial support for the biotechnologies 
 
Access to the human genome has marked a profound break in the pharmaceutical research 
paradigm. The accelerated advances in molecular genetics, owing to semi-industrial, robotised 
approaches,  are  revolutionising  the  diagnosis  of  hereditary  diseases;  they  are  likewise 
modifying the classic schemas of the comprehension of acquired diseases and opening the 
door to new therapeutic strategies of gene transfer ex vivo or in vivo, commonly called "DNA 
medication". At this biotechnological turning point, the pharmaceutical industry has to modify 
its strategies according to two principles: the establishment of a critical scale and linkage with 
life-sciences research and the CSBs in order to integrate the methods and advances of the 
biotechnologies. This imperative accounts for the groupings and restructurings of industrial 
firms at world level (with a decrease in the number of their active patents), and their multiple 
forms of partnerships, in the United States, Great Britain and, more recently, Germany, with 
small  biotechnology  companies  or  research  structures  to  handle  innovation,  namely  the 
different steps of the development of the invention of a new medication, from  the discovery 
of the active compound through preclinical and clinical trials to the final commercialisation. 
Upstream,  over  the  past  fifteen  years,  one-third  of  the  new  drugs  have  been  discovered 
through  the  identification  of  targets  in  the  genome.  Downstream,  the  economic  stakes  of 
biotherapeutics  are considerable, with  industry's  estimates for the field of cytokines alone 
indicating  a  world  market  of  $3  billion  in  1997,  while  forecasts  on  DNA  medication all 
anticipate  some  300  billion  francs  by  2010  (equivalent  to  one-third  of  the  present  world 
market for etical pharmaceuticals), 20 billion francs of which would go to France. 
In  the  United  States,  most  of  the  recombinant  proteins  (about  70  %)  have  resulted  from 
research spin-offs and been subsequently commercialised by the major pharmaceutical groups. 
This start-up dynamic in the biotechnologies may be explained by several factors : 
  The new technological skills mobilised  through the advances of molecular biology have 
not  been  anticipated  by  the major pharmaceutical  companies, who show great  inertia 
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  The replacement effect : the incentive for an existing company is less than for the later 
arrivals, who have new opportunities, whilst the elders would be creating competition for 
their own products.  
 
These factors shed light on processes in the United States whereby the innovation process 
upstream  is  broken  up  into  a  plethora  of small research companies  which are sometimes 
absorbed  because  of  financial  obstacles  (the  example  of  Genentech,  world  leader  in 
recombinant proteins, bought up at 60 % by La Roche-Hoffmann in 1990, is often cited), 
while downstream there are concentrations and network co-operations through share-holdings 
by the major groups and every imaginable kind of partnership. 
 
France, which had a first-ranking position in medications, has suffered a considerable loss of 
competitiveness over the past twenty years, with the last major therapeutic groups coming 
from abroad and especially the United States. If the commercialisation of new compounds is 
taken as an indicator, France's decline is marked by the passage from second place worldwide 
in 1974 to seventh in 1994 (Barral 1995). In the area of industrial production of recombinant 
proteins,  it  suffers  from  considerable  backwardness,  which  reflects  the  inadequacy  of  the 
fundamental research in the physiology of these proteins but also the weakness of French 
pharmaceutical companies' investment and their integration of the latest scientific knowledge 
in order to achieve the neccessary technological leap. In fact, companies position themselves 
competitively in function of their ability to develop collaborations, with academic research 
upstream but also with small biotechnology companies to absorb their specific skills. At the 
same  time,  they  guarantee  these  companies  commercial  outlets,  and  their  financial 
contributions or contracts provide funds necessary for the pursuit of their research. Indeed, 
there are very few CSBs which achieve a critical size and profitability without relying on 
major pharmaceutical groups. 
 
 
In terms of structure, the French pharmaceutical sector is fragmented, with a small number of 
major groups, recently internationalised and in the process of restructuring, and many SMEs 
that are not capable, internally or externally, of assuming the R&D efforts necessary for a 
technological  breakthrough.  In  terms  of  organisation,  the  French  groups  have  mainly 
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means of channelling public resources (both financial and scientific) into a private industrial 
group.  The  latter,  with  its  publicity  about  its  gene  therapy  programme,  presented  as  an 
integrated  activity  mastering  the  entire  chain  from  research  to  production  and  future 
commercialisation, has, through its monopolistic position, indirectly blocked the development 
of  small  "artisanal"  gene  therapy  centres  in  the  university  hospital  centres  and  dissuaded 
public policy-makers from supporting the creation of small biotechnology enterprises coming 
out  of  academic  research.  In  addition,  Rhône-Poulenc-Rohrer,  in  the  context  of  an  R&D 
strategy that is now international, finally externalised its technological developments of gene 
therapy to the United States in the Gencell network. 
 
The  French  advantage  of  a  therapeutic  "specialisation"  (Casper  1999)  of  biotechnologies, 
initiated by the AFM's research activity and  supported by the needs for a potential for high-
level  clinical  research  in  gene  therapy,  thus  came  up  against  the  obstacle  of  a  lack  of 
involvement  on  the  part  of  French  industry.  With  the  same  strategy  of  externalisation, 
moreover, French companies have privileged ties with American CSBs since the 1990s. They 
generate  very  few  start-ups  in  France,  unlike  the  computer  sector,  and  establish  few 
collaborations with existing companies (Transgène, Genset, etc.). This absence of relays for 
the  development  of  the  French  biotechnologies  leads  the  latter  to  sign  joint-venture 
agreements with foreign firms, with the long-term risk of relocation in proximity to their 
partners. 
In  the  absence  of  this  linkage,    although  the  public  policy-makers  and  companies  have 
integrated the institutional dimension of diffusion mechanisms, there is no "quasi-natural" 
continuity,  like  that  of  Anglo-American  sites,  between  institutions  producing  knowledge, 
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CONCLUSION  :  INNOVATION  SYSTEM  PERFORMANCES  IN  THE 
BIOTECHNOLOGIES  AND  LEARNING  PROCESS 
 
On  the  level  of  performances,  Europe's  lag  behind  the  United  States  in  biotechnologies 
companies is diminishing: Ernst and Young's 1999 survey confirms the European upsurge 
(1,178  companies  and  a  total  of  45,823  employees,  compared  to  1,287  companies  with 
153,000 employees in the US). After a belated takeoff, two years behind Germany, France has 
entered a phase of structuring and maturation of its innovative biotechnologies. It now has 140 
companies  (compared  to  220  in  Germany  and  280  in  the  UK),  employing  some  3,000 
individuals for a turnover of 600 million francs and a research budget of 1 billion francs. 
Three companies are listed on the stock markets, with Genset (genomics) and Transgène (gene 
therapy) ranking fifth and eleventh, respectively, on the capital markets (Ernst and Young 
1999). 
The public authorities' commitment to promoting programmes and the improvement of the 
overall institutional framework have stimulated the dynamics of the "sector", as can be seen 
from the creation of some twenty new companies in 1999. Eighteen incubators have come into 
being throughout the country with 107 million francs' support from the Ministry.  
Despite the worldwide decline in biotechnologies investment (their stocks underwent a 50 % 
drop in 1998-1999) because of competition from the information technologies, venture capital 
has maintained its contributions to European biotechnology companies, notably those oriented 
towards pharmaceutical applications. Nonetheless, no pharmaceutical product coming from 
the biotechnology companies has yet arrived on the market in France; the first British product 
was released in 1999. 
 
On the institutional level, the presence of mission-oriented elements in the new schemes raises 
the risk that the State will replace initiatives by the main protagonists in the science-industry 
partnerships,  which are beginning to  proliferate under the favourable influence of general 
diffusion-oriented measures.  Rather than seeking to  dictate the downstream phases of co-
ordination between public research, emerging companies and industry, where decentralised 
"intermediate institutions" supported by local communities would facilitate the transfers, the 
State should concentrate its interventions on the upstream stages. In this way, it might provide 
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  a  more  stimulating  financial  focus  on  research  programmes  on  genomics  and  its 
biotechnological applications and the new training programmes needed,  
  funding for company incubation before the arrival of venture capitalists and investors, 
which would permit more flexible projects through the mobility of potential creators and 
the recombination of resources,  
  a tax system for stock options that does not penalise young creators and thus discourage 
their relocation. 
 
On the level of public-policy organisation, examples from abroad, notably Anglo-American 
and German, show that the coherence of the public policy-making, its impetus-giving role and 
its  continuity  for  the  development  of  biotechnologies  are  facilitated  by  the  co-ordinated 
involvement  of  certain  major  public  players.  In  France,  the  stratified  accumulation  of 
ministerial  or  interministerial  commissions  and  committees  is  due  to  be  replaced  by  an 
agency-like structure for dialogue; this body would rely on the Life Sciences Co-ordinating 
Committee created in September 1999 for the strategic aspects of scientific policy and would 
work  closely  with  the  professional  institutions  of  the  biotechnologies,  the  pharmaceutical 
industry and the financial investors for development issues. 
 
The stages of an innovation process are not linear; rather, they overlap and interpenetrate, 
producing a "cumulative irreversibility" because of incremental innovations. In spite of the 
present combination of partially contradictory institutional schemes for the development of a 
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